Acta Scientific Pharmacology

Editorial Volume 2 Issue 9

Statin Therapy and COVID-19

Hind Shakir Ahmed*

Department of Chemistry/College of Education for Pure Science (Ibn Al-Haitham)/University of Baghdad, Iraq

*Corresponding Author: Hind Shakir Ahmed, Department of Chemistry/College of Education for Pure Science (Ibn Al-Haitham)/University of Baghdad, Iraq.

Received: July 22, 2021; Published: August 01, 2021

COVID-19 is an infection caused by a new coronavirus named sever acute respiratory syndrome (SARS-CoV-2). One of the endocytic route for the virus is via angiotensin converting enzyme (ACE2), which is vastly expressed in the lungs, heart, gastrointestinal tract and kidney, hence disturbing the cardiovascular system and the immune system. The overexpression of ACE2 was documented to improve viral entrance and intracellular replication. Moreover, COVID-19, may also use ACE2 as a receptor to initiate infection, foremost to various complications. It is also more probable to lead to poor consequences in obese patients and those with metabolic syndrome or cardiovascular disease. Due to the fact that viral infection often disturbs the cardiovascular system, causing myocardial infarction, viral myocarditis, tachyarrhythmia and stress cardiomyopathies, which have been recognized as risk factors for severe COVID-19 in various large case analysis from China, Italy, and the United States. It has been proposed that (3-hydroxy‑3-methyl-glutaryl-CoA reductase) inhibitors (statins) can decrease the risk of cardiovascular complications among COVID-19 patients. Using of these drugs to treat hyperlipidemia and its pleiotropic effects have been revealed to decrease cytokines in several non-infective situations. Treatment with statin for long-term associates with enhanced outcome in the setting of bacterial pneumonia and influenza.


Citation: Hind Shakir Ahmed. “Statin Therapy and COVID-19". Acta Scientific Pharmacology 2.9 (2020): 01.


Copyright: © 2021 Hind Shakir Ahmed. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate36%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US